Reuters logo
BRIEF-ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII
2017年11月15日 / 晚上6点33分 / 1 个月前

BRIEF-ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

Nov 15 (Reuters) - Ultragenyx Pharmaceutical Inc:

* ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

* ULTRAGENYX PHARMACEUTICAL - OPINION FOR VESTRONIDASE ALFA FROM COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE IS EXPECTED IN H1 2018​

* ULTRAGENYX PHARMACEUTICAL INC - ‍MEPSEVII WILL BE AVAILABLE TO PATIENTS IN U.S. LATER IN NOVEMBER​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below